Nooms own internal data also shows that the likelihood of experiencing side effects increases significantly as dosages increase
Date: November 16, 2025 Source: Cochrane Summary: GLP-1 drugs like tirzepatide and semaglutide offer powerful weight-loss effects but come with unanswered questions about long-term safety, side effects, and global accessibility
Potential risks include: Overdosing, which can result in severe nausea, vomiting, or hypoglycemia
These data are used for regulatory approval
What Happens After You Stop GLP-1 Medication
Meanwhile, the emergence of orally active small-molecule GLP-1 receptor agonists like danuglipron and orforglipron, which are resistant to enzymatic degradation, marks a major advance in patient-friendly drug delivery